Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Harbin Pharmaceutical Group CoSHSE:600664 -10.00%66 Return-on-Tangible-Equity is 12.28% as of Mar. 2026, which is 44% above its 10-year median of 8.55. GuruFocus rates SHSE:600664 with a GF Score™ of 66/100 and a GF Value™ of ¥3.51 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 899 Drug Manufacturers companies, Harbin Pharmaceutical Group Co ranks worse than 55.95% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Harbin Pharmaceutical Group Co's annualized net income for the quarter that ended in Mar. 2026 was ¥645 Mil. Harbin Pharmaceutical Group Co's average shareholder tangible equity for the quarter that ended in Mar. 2026 was ¥5,247 Mil. Therefore, Harbin Pharmaceutical Group Co's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was 12.28%.
The historical rank and industry rank for Harbin Pharmaceutical Group Co's Return-on-Tangible-Equity or its related term are showing as below:
SHSE:600664'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -27.34 Med: 8.55 Max: 13.88
Current: 6
During the past 13 years, Harbin Pharmaceutical Group Co's highest Return-on-Tangible-Equity was 13.88%. The lowest was -27.34%. And the median was 8.55%.
SHSE:600664's Return-on-Tangible-Equity is ranked worse than 55.95% of 899
companies
in the Drug Manufacturers industry
Industry Median: 7.95
vs SHSE:600664: 6.00
Harbin Pharmaceutical Group Co (SHSE:600664) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Harbin Pharmaceutical Group Co Return-on-Tangible-Equity Related Terms
Harbin Pharmaceutical Group Co Return-on-Tangible-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Harbin Pharmaceutical Group Co Return-on-Tangible-Equity Chart
SHSE:600664 vs ZTS, UTHR: Return-on-Tangible-Equity Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Harbin Pharmaceutical Group Co's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Harbin Pharmaceutical Group Co Return-on-Tangible-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Harbin Pharmaceutical Group Co's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Harbin Pharmaceutical Group Co's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 12.28% mean?
Harbin Pharmaceutical Group Co (SHSE:600664) has a Return-on-Tangible-Equity of 12.28% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Harbin Pharmaceutical Group Co and its competitors. This is 44% above median its historical median of 8.55. According to the industry distribution chart, Harbin Pharmaceutical Group Co ranks #503 out of 899 companies in the Drug Manufacturers industry, placing it in the top 56%.
Is Harbin Pharmaceutical Group Co's Return-on-Tangible-Equity too high?
Harbin Pharmaceutical Group Co's current Return-on-Tangible-Equity of 12.28% is 44% above median its 10-year median of 8.55. The Drug Manufacturers industry median Return-on-Tangible-Equity is 7.95. Harbin Pharmaceutical Group Co's value of 12.28% is 54.5% above this industry median. Based on the distribution chart, Harbin Pharmaceutical Group Co ranks #503 out of 899 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Harbin Pharmaceutical Group Co has a GF Score™ of 66/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Harbin Pharmaceutical Group Co's Return-on-Tangible-Equity compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Harbin Pharmaceutical Group Co ranks #503 out of 899 companies for Return-on-Tangible-Equity. This places Harbin Pharmaceutical Group Co in the lower half of its industry. The industry median Return-on-Tangible-Equity is 7.95. Harbin Pharmaceutical Group Co's value of 12.28% is 54.5% above this benchmark. While the company's 10-year median is 8.55 vs. the industry median of 7.95, Harbin Pharmaceutical Group Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Drug Manufacturers company?
The median Return-on-Tangible-Equity among Drug Manufacturers companies is 7.95, based on 899 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Harbin Pharmaceutical Group Co's current Return-on-Tangible-Equity of 12.28% is 54.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Harbin Pharmaceutical Group Co and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Equity is 7.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Harbin Pharmaceutical Group Co's current Return-on-Tangible-Equity is 12.28%, which is 44% above median its own 10-year median of 8.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Harbin Pharmaceutical Group Co stock overvalued right now?
Based on GuruFocus' analysis, Harbin Pharmaceutical Group Co (SHSE:600664) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥3.51, compared to a current price of ¥5.40 — trading 53.8% above its estimated fair value. The current Return-on-Tangible-Equity is 12.28%, which is 44% above median its 10-year median of 8.55 and 54.5% above the Drug Manufacturers industry median of 7.95. Harbin Pharmaceutical Group Co's overall GF Score™ is 66/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Harbin Pharmaceutical Group Co (SHSE:600664), the current Return-on-Tangible-Equity is 12.28% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Harbin Pharmaceutical Group Co (SHSE:600664) Overvalued in 2026?
Based on GuruFocus' analysis, Harbin Pharmaceutical Group Co stock appears to be overvalued.
The current stock price of ¥5.40 is trading 53.8% above its estimated GF Value™ of ¥3.51.
GuruFocus considers Harbin Pharmaceutical Group Co to be Significantly Overvalued.
Key valuation signals for SHSE:600664:
Return-on-Tangible-Equity: 12.28% (44% above median its 10-year median of 8.55)
GF Value™: ¥3.51 vs. price of ¥5.40 (53.8% above fair value)
Industry Position: 54.5% above the Drug Manufacturers median (#503 of 899)
No single metric tells the full story. See the SHSE:600664 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Harbin Pharmaceutical Group Co Business Description
Harbin Pharmaceutical Group Co Ltd is engaged in manufacturing, trading and research and development of pharmaceuticals. The company is organized into seven business segments - Antibiotics, Small-Molecular drug preparations, OTC and healthcare products, Modern Chinese medicines, Biopharmaceuticals, Animal vaccines, and medicine circulations. The company sells its products across China and fifty other countries. Some of its brands are - Hayao, Sanjing, Gaizhonggai, Hutong, and Shiyitang.
66GF Score
Get the complete analysis for SHSE:600664
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600664 has been successfully added to your 
